Liquidia Corporation
Support and Resistance Levels
Past performance
News About LQDA
All events for LQDA
All deals for LQDA
Financial Ratios
Financial Statements
LQDA vs Sector & Peers
About Liquidia Corporation
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina. Website liquidia.com
Headquarters Morrisville, NC, US